Massachusetts General Hospital Evaluation of DePuy ASR Hip System



Status:Active, not recruiting
Conditions:Arthritis, Osteoarthritis (OA)
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:21 - Any
Updated:10/21/2017
Start Date:September 2012
End Date:December 2022

Use our guide to learn which trials are right for you!

Clinical Follow-up of ASR Patients Post-Recall

DePuy Orthopaedics has issued a voluntary recall of the ASR hip replacement system due to a
higher than expected revision rate reported in the England/Wales and Australian national
joint registries. There are two types of ASR hip implants used for total hip replacement
surgery:

- ASR XL Hip System

- ASR Hip Resurfacing System Massachusetts General Hospital (MGH) in Boston, USA is the
study sponsor. MGH is conducting this study with the help of funding from DePuy
Orthopaedics. MGH will collect and analyze clinical information from 5,000 subjects
around the world. The countries include the United States of America, Australia, South
Africa, England, Denmark, Finland and Sweden. MGH will collect and analyze blood test
results, X-rays, soft tissue imaging and how well the ASR hips are functioning. MGH will
analyze the data annually for 6 years.

The purpose of this study is to follow patients who have the ASR hip system for the next 6
years. The findings of this study may help surgeons to make better informed decisions about
monitoring and treatment of patients with ASR hip systems.

Description of the Subject Population:

- Adults who have previously undergone a surgery implanting the DePuy ASR XL Acetabular
Hip System or ASR Hip Resurfacing System;

- ASR patients who are already being followed-up by their surgeon at least once a year.
This routine follow-up care consists of a clinic visit, blood tests, X-rays and possibly
an MRI, Ultrasound or CT scan.

Inclusion Criteria

1. Any patient with on-label use of the ASR-XL or ASR component system currently
implanted.

2. Able to provide informed consent previously approved by institution's Institutional
Review board (IRB) or ethics committee (EC).

3. Able to return for follow-up.

4. Able to complete the required patient reported outcome measures.

Exclusion Criteria

1. Any patient with off-label use indications for the ASR-XL or ASR component system.

2. Any patient who received the ASR-XL implant as a result of a hip resurfacing
conversion or a revision THA.

3. Subjects with difficulty in comprehending the Informed Consent Form for any reason.

4. The subject refuses to allow their medical records to be inspected by the Sponsor,
representatives of the Sponsor, or the medical office staff.
We found this trial at
8
sites
York, Pennsylvania 17402
?
mi
from
York, PA
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fort Worth, Texas 76104
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
?
mi
from
Glenview, IL
Click here to add this to my saved trials
Grants Pass, Oregon 97527
?
mi
from
Grants Pass, OR
Click here to add this to my saved trials
32 Payneham Road
Stepney, South Australia 5069
?
mi
from
Stepney,
Click here to add this to my saved trials
Syracuse, New York 13214
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
Woodbury, Minnesota 55125
?
mi
from
Woodbury, MN
Click here to add this to my saved trials